Search

everythinglearnresearchcommunity

for

Search:↓

The review shows that skin symptoms like chronic fungal infections, hair loss, and skin depigmentation are key for early detection and management of APECED.

Key genes linked to immune response are upregulated in hair follicles and skin tissues in chronic discoid lupus erythematosus.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Ginseng, especially its component ginsenosides, can promote hair growth, reduce hair loss, and potentially treat conditions like alopecia by affecting cell pathways and cytokines.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Key genes linked to immune response are highly active in lupus-affected hair follicles.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Cholecystokinin may help reduce skin inflammation in psoriasis.

R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

More precise, personalized therapies are needed for autoimmune diseases.

Multi-omics techniques help understand the molecular causes of androgenetic alopecia.

Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

A 3-month treatment improved PCOS symptoms and reduced certain immune proteins.

SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.

Bacteria can help skin regenerate through a process called IL-1β signaling.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

The conference highlighted new dermatological treatments and emphasized early intervention and addressing conditions lacking evidence-based treatments.